Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

ATTAIN-1

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 3127

NCT05869903

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
6 mg Orforglipronn/rn/rn/rn/r
12 mg Orforglipronn/rn/rn/rn/r
36 mg Orforglipronn/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • 6 mg Orforglipron: endpoint not reported
  • 12 mg Orforglipron: endpoint not reported
  • 36 mg Orforglipron: endpoint not reported